Liver Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Experimental Antibody for Treatment-Resistant Liver Cancer
(Posted: 05/15/2012) - In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for liver transplants or other localized therapies, and who did not benefit from or could not tolerate treatment with sorafenib, will be treated with intravenous TRC105 every 2 weeks.
Combining Systemic Therapies for Patients with Advanced Liver Cancer
(Posted: 03/20/2012) - In this phase III trial, patients with unresectable, locally advanced or metastatic primary liver cancer who have good liver function (Child-Pugh score A) will receive sorafenib and be randomly assigned to also receive either doxorubicin or no additional therapy.
Testing Trabectedin in Pediatric Patients
(Posted: 06/30/2009) - In this phase I clinical trial, children with solid tumors that have either recurred or have not responded to previous treatment will be treated with trabectedin.
Combination Chemotherapy for Liver Cancer
(Posted: 11/29/2005, Updated: 11/07/2007) - In this clinical trial, researchers are adding a new drug called bortezomib to chemotherapy with doxorubicin to see if it can cause liver tumors to shrink or stop growing better than doxorubicin alone.
Targeted Therapy for Liver or Biliary Tract Cancer
(Posted: 02/21/2006, Updated: 06/04/2007) - In this clinical trial, researchers are testing the ability of a new drug called lapatinib to delay tumor growth and possibly improve the survival of patients with inoperable hepatocellular or biliary tract cancer. Lapatinib works by disrupting chemical signals that stimulate the growth and spread of cancer cells.
(Posted: 05/15/2012) - In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for liver transplants or other localized therapies, and who did not benefit from or could not tolerate treatment with sorafenib, will be treated with intravenous TRC105 every 2 weeks.
Combining Systemic Therapies for Patients with Advanced Liver Cancer
(Posted: 03/20/2012) - In this phase III trial, patients with unresectable, locally advanced or metastatic primary liver cancer who have good liver function (Child-Pugh score A) will receive sorafenib and be randomly assigned to also receive either doxorubicin or no additional therapy.
Testing Trabectedin in Pediatric Patients
(Posted: 06/30/2009) - In this phase I clinical trial, children with solid tumors that have either recurred or have not responded to previous treatment will be treated with trabectedin.
Combination Chemotherapy for Liver Cancer
(Posted: 11/29/2005, Updated: 11/07/2007) - In this clinical trial, researchers are adding a new drug called bortezomib to chemotherapy with doxorubicin to see if it can cause liver tumors to shrink or stop growing better than doxorubicin alone.
Targeted Therapy for Liver or Biliary Tract Cancer
(Posted: 02/21/2006, Updated: 06/04/2007) - In this clinical trial, researchers are testing the ability of a new drug called lapatinib to delay tumor growth and possibly improve the survival of patients with inoperable hepatocellular or biliary tract cancer. Lapatinib works by disrupting chemical signals that stimulate the growth and spread of cancer cells.